Noom vs Medvi: Behavioral App Versus Medication Program

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Full head-to-head: PlexusDx vs MEDVi →

This is an independent editorial review. PlexusDx has no commercial relationship with Medvi or Noom, and no affiliate links or paid placements appear here.

Noom and Medvi start from different philosophies. Noom built its name on behavior change delivered through an app, later adding a medication option; Medvi is medication-first, organized around a compounding pharmacy. Comparing them is really a question of what you want at the center of your plan — habits or a prescription. Both are among many weight-management options live in April 2026.

Two philosophies of weight management

One approach treats weight as a behavioral and psychological challenge to be coached through habit change; the other treats it as a metabolic target best addressed with medication. In practice the line blurs — Noom now offers a medication add-on, and medication programs increasingly bundle coaching and support — but the center of gravity still differs, and that difference shapes the daily experience, the cost, and what you are expected to do between check-ins. Knowing which philosophy anchors a program helps you match it to how you actually want to work.

Noom's psychology-first, app-based model

Noom (Noom, Inc.) operates as an app-based subscription with a medication add-on: behavioral coaching and tracking through the app, plus optional virtual clinical evaluation, provider-issued prescriptions, and dispensing of brand-name or compounded GLP-1 therapy through licensed pathways. Current program details are posted at Noom's official website.

Medvi's medication-first, compounded model

Medvi (Medvi Wellness) is built around a telehealth-plus-compounded-pharmacy program, with medication at the center rather than as an add-on. Its terms are posted on Medvi's official website. Across medication-first programs, monthly totals commonly fall in the $200—$700+ range once evaluation, medication, and dispensing are combined.

What the GLP-1 evidence base shows

Where medication enters either plan, the same compound class applies. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide act on appetite, satiety, and gastric emptying, with evidence from STEP (semaglutide, NEJM 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). Coaching and medication address different levers; the pharmacology of the drug is constant, whether it is delivered as a Noom add-on or through a medication-first program like Medvi.

The biology behind behavior and appetite

Habits and biology are not separate. Variants in FTO, GLP1R (the receptor every GLP-1 compound targets), MC4R (central to satiety and energy balance), and TCF7L2 shape appetite and glucose handling that behavior alone cannot fully override. These are pathway-level markers, not drug-response predictors, but they explain part of why weight is stubborn. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights across those genes.

Pairing genetics with your plan

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — with a genetic read that complements either a habit-first or medication-first plan. That context sits underneath whichever philosophy you choose to build your program around.

Not affiliated: PlexusDx has no commercial ties to Medvi or Noom and received no compensation for this review.

Related reading on PlexusDx: GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone.

Disclaimer: This article is educational. PlexusDx is not affiliated with Medvi or Noom and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Frequently Asked Questions

Is Noom a medication program or a coaching app?

Noom began as an app-based behavioral coaching subscription and later added a medication option. It combines habit tracking and psychology-based coaching with an optional GLP-1 add-on through virtual care. Medvi, by contrast, is medication-first. Current details for each are on their own websites.

Can coaching replace GLP-1 medication?

They target different levers. Behavioral coaching supports habits and adherence, while GLP-1 medication acts directly on appetite and satiety biology. Many people use both, and the trial evidence for GLP-1 effect sizes reflects the medication itself, not the coaching layered around it.

Why does genetics matter if I focus on behavior?

Because appetite and glucose handling are partly genetic. Pathway-level variants in FTO and MC4R, and TCF7L2 shape how hard behavior change is and what a protocol is working against. The Precision Peptide Genetic Test maps that context, though it does not predict medication response.

How does PlexusDx fit a behavior-first plan?

PlexusDx pairs semaglutide and tirzepatide with an upstream genetic read that complements coaching or medication alike. The pathway-level insight on FTO, MC4R adds biological context to whichever approach — habits or prescription — sits at the center of your plan.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education